Detalhe da pesquisa
1.
Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data.
Qual Life Res
; 32(3): 827-839, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36245019
2.
The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results.
Stroke
; 53(5): 1802-1812, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354299
3.
Health-related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R-04.
Cancer
; 128(17): 3233-3242, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749631
4.
Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial.
Am Heart J
; 237: 90-103, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33745898
5.
On the properties of the toxicity index and its statistical efficiency.
Stat Med
; 40(6): 1535-1552, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33345351
6.
Visualizing adverse events in clinical trials using correspondence analysis with R-package visae.
BMC Med Res Methodol
; 21(1): 244, 2021 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753452
7.
A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
J Biopharm Stat
; 28(3): 562-574, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-28858566
8.
A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Stat Med
; 36(2): 280-290, 2017 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27060889
9.
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Eur Heart J
; 37(19): 1504-13, 2016 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26614823
10.
Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding.
Entropy (Basel)
; 17(8): 5288-5303, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27156869
11.
Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Stat Med
; 33(22): 3815-29, 2014 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24825779
12.
Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation.
J Pediatr Hematol Oncol
; 35(4): e149-52, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23274384
13.
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Cancer Prev Res (Phila)
; 16(11): 631-639, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37756580
14.
A multi-laboratory preclinical trial in rodents to assess treatment candidates for acute ischemic stroke.
Sci Transl Med
; 15(714): eadg8656, 2023 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729432
15.
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
Braz J Biom
; 40(4): 453-468, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357386
16.
Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30.
NPJ Breast Cancer
; 8(1): 123, 2022 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36402796
17.
HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.
Mol Cancer Ther
; 21(1): 217-226, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34675120
18.
Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancer-Specific Quality of Life Questionnaire.
Clin Ther
; 43(7): 1245-1252, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34183169
19.
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
PLoS One
; 16(6): e0252665, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081738
20.
Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.
J Clin Oncol
; 39(34): 3800-3812, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34554865